|Dr. Mark Pruzanski M.D.||Founder, Chief Exec. Officer, Pres and Director||1.04M||7.64M||49|
|Mr. Sandip S. Kapadia||Chief Financial Officer and Treasurer||282.06k||N/A||47|
|Mr. David Shapiro M.D., Ph.D.||Chief Medical Officer and Exec. VP of Devel.||688.88k||295.76k||63|
|Dr. Rachel L. McMinn Ph.D.||Chief Bus. and Strategy Officer||592.51k||N/A||44|
|Ms. Lisa Bright||Pres of International||614.81k||N/A||49|
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 9.